Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment

KRA Abdellatif, RB Bakr - Medicinal Chemistry Research, 2021 - Springer
Pyrimidine ring and its fused derivatives including pyrazolo [3, 4-d] pyrimidine, pyrido [2, 3-d]
pyrimidine, quinazoline, and furo [2, 3-d] pyrimidine compounds had received much interest …

Cyanothioacetamide: a polyfunctional reagent with broad synthetic utility

VD Dyachenko, IV Dyachenko… - Russian Chemical …, 2018 - iopscience.iop.org
The review integrates and analyzes the published data on the chemical reactivity of α-
cyanothioacetamide, a convenient starting compound for the preparation of activated …

Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases

R Liu, CG Proud - Acta Pharmacologica Sinica, 2016 - nature.com
Eukaryotic elongation factor 2 kinase (eEF2K) is an unusual protein kinase that regulates
the elongation stage of protein synthesis by phosphorylating and inhibiting its only known …

Eukaryotic elongation factor 2 kinase (eEF2K) in cancer

X Wang, J Xie, CG Proud - Cancers, 2017 - mdpi.com
Eukaryotic elongation factor 2 kinase (eEF2K) is a highly unusual protein kinase that
negatively regulates the elongation step of protein synthesis. This step uses the vast majority …

An overview on synthetic and pharmaceutical prospective of pyrido[2,3‐d]pyrimidines scaffold

P Yadav, K Shah - Chemical Biology & Drug Design, 2021 - Wiley Online Library
Abstract Pyrido [2, 3‐d] pyrimidine, a fused hetero‐bicyclic nucleus containing pyridine and
pyrimidine rings has attained the momentary attention in the sphere of multicomponent …

Synthesis of heterocyclic scaffolds through 6-aminouracil-involved multicomponent reactions

GM Ziarani, NH Nasab, N Lashgari - RSC advances, 2016 - pubs.rsc.org
This review presents the advances in the use of 6-aminouracil as a starting material in the
synthesis of various heterocyclic structures such as pyrido-, pyrrolo-, and pyrimido …

eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA

Y Wu, J Xie, X Jin, RV Lenchine, X Wang… - Biochemical …, 2020 - portlandpress.com
Emerging advances in cancer therapy have transformed the landscape towards cancer
immunotherapy regimens. Recent discoveries have resulted in the development of clinical …

Designing an eEF2K-targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells

Y Liu, Y Zhen, G Wang, G Yang, L Fu, B Liu… - European Journal of …, 2020 - Elsevier
Eukaryotic elongation factor 2 kinase (eEF2K) is a key α-kinase that negatively regulates the
extension step of protein synthesis, which consumes most of the energy and amino acids …

Molecular Dynamics Simulation-Driven Focused Virtual Screening and Experimental Validation of Inhibitors for MTDH-SND1 Protein–Protein Interaction

Y Xu, X Guo, D Yan, X Dang, L Guo, T Jia… - Journal of Chemical …, 2023 - ACS Publications
Protein–protein interactions (PPIs), in general, are attractive yet challenging drug targets. As
a typical PPI, MTDH-SND1 interaction has recently been reported to be a promising drug …

Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy

Y Guan, S Jiang, W Ye, X Ren, X Wang, Y Zhang… - Cell Death & …, 2020 - nature.com
Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and
contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors …